Swinburne researchers investigate effects of medicinal cannabis on drivers

The study will be conducted on-site at Swinburne's driving simulator facilities within the Drugs and Driving Research unit.
In summary
- Dr Amie Hayley and Professor Luke Downey from Swinburne’s Drugs and Driving Research Unit have received funding from the federal government’s Road Safety Innovation Fund
- This study will be the first to use innovative technologies to examine the effect of medicinal cannabis products available in Australia on driving ability
- As medicinal cannabis becomes increasingly available, the researchers say solutions to identify and reduce cannabis impaired driving are urgently needed to promote traffic safety
A Swinburne study into the effects on medical cannabis on driving ability has received $345,951 in funding from the federal government’s Road Safety Innovation Fund. Led by Dr Amie Hayley and Professor Luke Downey from the Centre for Human Psychopharmacology, it will also investigate how we can use technology to measure driving impairment.
The study is the first of its kind and will be conducted within Swinburne’s Drugs and Driving Research unit, which is led by Professor Downey.
‘We are grateful for this grant, and especially for the opportunity to further our research in this space,’ says Professor Downey. ‘It is critical to quantify the potential risk these road users take when they get behind the wheel and develop methods to protect these vulnerable patients, as well as all road users.’
Filling a gap in knowledge
Many Australian consumers of medicinal cannabis access products that contain delta-9-tetrahydrocannabinol, better known as THC, which is a controlled drug under the Australian Poisons Standard, which provides a uniform approach to control the availability and accessibility of substances that can be used as ingredients in medicine.
‘A controlled drug is a medicine that may only be prescribed by an authorised healthcare professional. As of February 2021, over 100,000 special access permits for medicinal cannabinoid products has been approved, a large proportion of which contains THC,’ explains Dr Hayley, who is Principal Investigator for the study.
’There is no definitive legal, clinical or road safety recommendation as to the length of time that medicinal cannabis products can be detected, nor whether the use of these products contribute to increased risk of traffic collision,’ Professor Downey adds.
Using innovative technology
‘We will conduct a program of research that examines the use of innovative technology, such as driver monitoring systems, to protect vulnerable road users who may make the mistake of operating a vehicle when the medication is impairing their ability to control the vehicle,’ says Dr Hayley.
Driver monitoring systems monitor and detect a driver’s state and collect information to make an instant assessment about their capacity to drive safely. These technologies have already been highly effective in detecting and alerting drivers who are tired or distracted by creating a sound to reengage the driver.
‘Using our high-fidelity driving simulator and eye monitoring technologies, we will test the relationship between eye movements and driver behaviour to better understand the impact of medicinal cannabis use on driving performance in patients, as well as healthy adults,’ Professor Downey explains.
‘As medicinal cannabis becomes increasingly available, solutions to identify and reduce cannabis impaired driving are urgently needed to promote traffic safety. Through our research, we hope to uncover potential solutions to mitigate the risk of road trauma for these patients and all road users,’ says Dr Hayley.
Supporting road safety
The Road Safety Innovation Fund is awarded by the federal government’s Office of Road Safety.
The fund supports innovative projects designed to reduce the number of deaths and serious injuries on Australian roads and help create a safe and sustainable road transport system for everyone. Priority areas include improving road safety in regional and remote areas, reducing driver distraction and drug driving, improving safety for vulnerable road users and supporting road safety research and initiatives specific to the Australian context.
-
Media Enquiries
Related articles
-
- Health
World-first intravenous psychedelic trial to treat binge eating to launch
The world-first IV-administered psychedelic trial for binge eating disorder will kick off this year at Swinburne.
Thursday 10 April 2025 -
- Health
- Science
Swinburne to boost AI-driven design for dental devices with investment in H3D
Swinburne has invested in spinout company H3D, a cutting-edge tech company that is reinventing custom-fit devices using AI and automation.
Monday 31 March 2025 -
- Health
- Science
Medical cannabis mysteries to be unlocked by new five-year NHMRC project
A new Swinburne-led medical cannabis investigation aims to help close the knowledge gap surrounding the drug and its potential in society.
Wednesday 26 February 2025 -
- Health
- University
Swinburne educator excellence recognised in Australian Awards for University Teaching
Swinburne educators Dr Faith Kwa, Associate Professor Junhua Xiao, Dr Jessica Mackelprang and Dr James Williams were recognised for their teaching excellence in Health Sciences for thr 2024 Australian Awards for University Teaching.
Tuesday 25 February 2025 -
- University
- Sustainability
Swinburne surges into top 300 in QS Sustainability Rankings 2025
Swinburne University of Technology has climbed to number 270 in the world in the QS Sustainability Ranking 2025.
Wednesday 11 December 2024